CTLA4 和 LAG3 单核苷酸多态性对接受 BCMA CAR-T 细胞治疗的多发性骨髓瘤患者的临床影响

Clinical Impact of CTLA4 and LAG3 Single-Nucleotide Polymorphisms in Multiple Myeloma Patients Treated With BCMA CAR T-Cell Therapy.

更正：BRIDGE-2M：优化多发性骨髓瘤 CAR-T 治疗前的桥接治疗：美国医师改良双盲 Delphi 专家小组

Correction: BRIDGE-2M: Optimizing Bridging Therapy Prior to CAR-T Therapy in Multiple Myeloma: A Modified Double-Blind Delphi Panel of US Physicians.

体弱患者接受 ciltacabtagene autoleucel 治疗的真实世界疗效和安全性：国际血液和骨髓移植研究中心的分析

Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant

Cilta-cel 在体弱 RRMM 中仍然有效，但衰弱与生存期缩短和毒性增加相关，支持制定个体化的 CAR-T 策略。

迈向多发性骨髓瘤的治愈：重新定义诱导治疗与自体干细胞移植的作用

Toward a Cure in Multiple Myeloma: Redefining Induction Therapy and the Role of Autologous Stem Cell Transplant.

多发性骨髓瘤中新型 CAR-T 细胞毒性的管理

Managing Novel CAR T-Cell Toxicities in Multiple Myeloma.

CAR-T 细胞疗法：在难治性骨髓瘤中工程化实现缓解

CAR-T Cell Therapy: Engineering Remission in Refractory Myeloma.

靶向 B 细胞成熟抗原的 CAR-T 细胞作为抗 G 蛋白偶联受体 C 类 5 组成员 D CAR-T 细胞治疗后进展性多发性骨髓瘤的挽救治疗

B-cell maturation antigen-targeted CAR T cell as a salvage therapy for progressive multiple myeloma after anti-G proteincoupled receptor, class C grou

Anito-cel，一种 d 结构域 BCMA CAR-T 细胞，用于难治性或复发性骨髓瘤的 1 期研究

Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma.

Anito-cel 治疗在重度经治的复发/难治性多发性骨髓瘤患者中导致了高缓解率。3 级或更高级别的细胞因子释放综合征和 ICANS 罕见。（由 Arcellx 和 Kite，一家吉利德公司资助；ClinicalTrials.gov 注册号：NCT04155749。）

iPSCs 在 BCMA 靶向治疗多发性骨髓瘤中的现状与前景

The Current Landscape and Prospects of iPSCs in BCMA-targeted Therapy for Multiple Myeloma.

体内 CAR-T 细胞疗法：缓解与持久性的决定因素

In vivo CAR T-cell therapy: determinants of response and durability.